Efficacy of an Electronic Health Management Program for Patients With Cardiovascular Risk: Randomized Controlled Trial
Overview
Authors
Affiliations
Background: In addition to medication, health behavior management is crucial in patients with multiple risks of cardiovascular mortality.
Objective: This study aimed to examine the efficacy of a 3-month Smart Management Strategy for Health-based electronic program (Smart Healthing).
Methods: A 2-arm randomized controlled trial was conducted to assess the efficacy of Smart Healthing in 106 patients with at least one indicator of poor disease control and who had hypertension, diabetes, or hypercholesterolemia. The intervention group (n=53) took part in the electronic program, which was available in the form of a mobile app and a Web-based PC application. The program covered 4 areas: self-assessment, self-planning, self-learning, and self-monitoring by automatic feedback. The control group (n=53) received basic educational material concerning disease control. The primary outcome was the percentage of participants who achieved their clinical indicator goal after 12 weeks into the program: glycated hemoglobin (HbA) <7.0%, systolic blood pressure (SBP) <140 mmHg, or low-density lipoprotein cholesterol <130 mg/dL.
Results: The intervention group showed a significantly higher success rate (in comparison with the control group) for achieving each of 3 clinical indicators at the targeted goal levels (P<.05). Only the patients with hypertension showed a significant improvement in SBP from the baseline as compared with the control group (72.7% vs 35.7%; P<.05). There was a significant reduction in HbA in the intervention group compared with the control group (difference=0.54%; P≤.05). In the intervention group, 20% of patients with diabetes exhibited a ≥1% decrease in HbA (vs 0% among controls; P≤.05).
Conclusions: A short-term self-management strategy-based electronic program intervention may improve clinical outcomes among patients with cardiovascular risks.
Trial Registration: ClinicalTrials.gov NCT03294044; https://clinicaltrials.gov/ct2/show/NCT03294044.
Dusing P, Schirmer S, Schafer S, Krogmann A, Sinning J, Werner N Front Cardiovasc Med. 2025; 12:1515598.
PMID: 39995964 PMC: 11847794. DOI: 10.3389/fcvm.2025.1515598.
Cerron Tito L, Delgado Baca J, Espinola-Sanchez M, Vilca L, Huancahuire-Vega S Health Psychol Behav Med. 2024; 12(1):2430967.
PMID: 39624787 PMC: 11610319. DOI: 10.1080/21642850.2024.2430967.
Dusing P, Eckardt I, Schirmer S, Sinning J, Werner N, Bonner F Eur Heart J Digit Health. 2023; 4(3):207-215.
PMID: 37265862 PMC: 10232292. DOI: 10.1093/ehjdh/ztad012.
Park H, Jeong S, Chung H, Soh J, Hyun Y, Bang S Int J Med Inform. 2022; 166:104844.
PMID: 36007433 PMC: 9381936. DOI: 10.1016/j.ijmedinf.2022.104844.
Kanai M, Toda T, Yamamoto K, Akimoto M, Hagiwara Y Circ Rep. 2022; 4(7):322-329.
PMID: 35860354 PMC: 9257458. DOI: 10.1253/circrep.CR-22-0024.